Trials / Completed
CompletedNCT01755377
New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease
Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 63 (actual)
- Sponsor
- Barcelona Centre for International Health Research · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Chagas disease is endemic to Latin America, and is of emerging importance in non-endemic countries because migration of people infected with T. cruzi. Current methods for diagnosis of T. cruzi infection are not ideal. Existing drugs for treatment are very limited, produce severe side-effects, and their effectiveness cannot be properly evaluated. Reliable biomarkers for prognosis, early diagnosis and effectiveness of treatment will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Benznidazole |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2016-05-01
- Completion
- 2016-06-01
- First posted
- 2012-12-24
- Last updated
- 2016-08-22
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01755377. Inclusion in this directory is not an endorsement.